AR090865A1 - ORAL PHARMACEUTICAL FORM FOR THE PREVENTION OF VASCULAR DISEASES, COMPRESSED AS PHARMACEUTICAL FORM AND GELATINE CAPSULE AS PHARMACEUTICAL FORM - Google Patents

ORAL PHARMACEUTICAL FORM FOR THE PREVENTION OF VASCULAR DISEASES, COMPRESSED AS PHARMACEUTICAL FORM AND GELATINE CAPSULE AS PHARMACEUTICAL FORM

Info

Publication number
AR090865A1
AR090865A1 ARP130101424A ARP130101424A AR090865A1 AR 090865 A1 AR090865 A1 AR 090865A1 AR P130101424 A ARP130101424 A AR P130101424A AR P130101424 A ARP130101424 A AR P130101424A AR 090865 A1 AR090865 A1 AR 090865A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical form
prevention
acceptable salts
compressed
pharmacologically acceptable
Prior art date
Application number
ARP130101424A
Other languages
Spanish (es)
Inventor
Magalhes Lahmann Walker
Oliveira Dos Santos Filho Hilton
Renno Dos Mares Guia Thiago
Campos Junior Aguinaldo
Original Assignee
Hypermarcas S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypermarcas S A filed Critical Hypermarcas S A
Publication of AR090865A1 publication Critical patent/AR090865A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Abstract

Formas farmacéuticas orales, destinadas al uso terapéutico en la prevención de enfermedades cardio y cerebrovasculares en mamíferos, preferentemente en humanos. De forma particular la presente se refiere a un comprimido que comprende (a) uno o más inhibidores de HMG-CoA reductasa, (b) uno o más antagonistas de receptores de angiotensina II y (c) uno o más diuréticos de la clase de las tiazidas, en donde (a) no está en contacto físico con (b) ó (c). Reivindicación 3: Forma farmacéutica de acuerdo con la reivindicación 1 caracterizada porque (a) uno o más inhibidores de HMG-CoA reductasa son estatinas o sus sales farmacológicamente aceptables, estabilizadas con agentes alcalinizantes. Reivindicación 6: Forma farmacéutica de acuerdo con la reivindicación 3 caracterizada porque la estatina es atorvastatina o sus sales farmacológicamente aceptables en formas cristalina o amorfa. Reivindicación 8: Forma farmacéutica de acuerdo con la reivindicación 7 caracterizada porque el antagonista de los receptores de angiotensina II es losartán o sus sales farmacológicamente aceptables.Oral pharmaceutical forms, intended for therapeutic use in the prevention of cardio and cerebrovascular diseases in mammals, preferably in humans. In particular, this refers to a tablet comprising (a) one or more HMG-CoA reductase inhibitors, (b) one or more angiotensin II receptor antagonists and (c) one or more diuretics of the class of thiazides, where (a) is not in physical contact with (b) or (c). Claim 3: Pharmaceutical form according to claim 1 characterized in that (a) one or more HMG-CoA reductase inhibitors are statins or their pharmacologically acceptable salts, stabilized with alkalizing agents. Claim 6: Pharmaceutical form according to claim 3 characterized in that the statin is atorvastatin or its pharmacologically acceptable salts in crystalline or amorphous forms. Claim 8: Pharmaceutical form according to claim 7 characterized in that the angiotensin II receptor antagonist is losartan or its pharmacologically acceptable salts.

ARP130101424A 2012-04-26 2013-04-26 ORAL PHARMACEUTICAL FORM FOR THE PREVENTION OF VASCULAR DISEASES, COMPRESSED AS PHARMACEUTICAL FORM AND GELATINE CAPSULE AS PHARMACEUTICAL FORM AR090865A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102012009735-4A BR102012009735A2 (en) 2012-04-26 2012-04-26 ORAL PHARMACEUTICAL FORM FOR PREVENTION OF VASCULAR DISEASES, COMPRESSED AS PHARMACEUTICAL FORM AND JELLY CAPSULE AS PHARMACEUTICAL FORM

Publications (1)

Publication Number Publication Date
AR090865A1 true AR090865A1 (en) 2014-12-10

Family

ID=49482044

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101424A AR090865A1 (en) 2012-04-26 2013-04-26 ORAL PHARMACEUTICAL FORM FOR THE PREVENTION OF VASCULAR DISEASES, COMPRESSED AS PHARMACEUTICAL FORM AND GELATINE CAPSULE AS PHARMACEUTICAL FORM

Country Status (4)

Country Link
AR (1) AR090865A1 (en)
BR (1) BR102012009735A2 (en)
UY (1) UY34769A (en)
WO (1) WO2013159166A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102013028883A2 (en) * 2013-11-08 2015-10-06 Hypermarcas S A oral dosage form for the prevention of vascular diseases, tablet as a dosage form and gelatin capsule as a dosage form
KR101771766B1 (en) * 2013-12-30 2017-08-28 알보젠코리아 주식회사 Pharmaceutical combination comprising Angiotensin-Ⅱ Receptor Blocker and HMG-CoA Reductase Inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005039637A2 (en) * 2003-10-17 2005-05-06 Novartis Ag Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
NZ595127A (en) * 2009-02-11 2013-08-30 Cadila Pharmaceuticals Ltd Stable pharmaceutical composition for atherosclerosis

Also Published As

Publication number Publication date
BR102012009735A2 (en) 2014-04-15
UY34769A (en) 2013-11-29
WO2013159166A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
UY33536A (en) BICYCLIC INHIBITORS OF ACETIL-CoA-CARBOXYLASE AND USES OF THE SAME
CL2012003178A1 (en) Compounds derived from unsaturated nitrogen heterocycles or their pharmaceutically acceptable salts, such as pde10 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of diseases such as psychosis, parkinson's disease, depression, mood disorders and dementia.
CY1125290T1 (en) APPLICATION OF R-KETAMINE AND ITS SALTS AS DRUGS
SV2015005115A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
DOP2016000094A (en) COMPOUNDS DERIVED FROM BICYCLIC PIRIDYL FUSIONED TO RING AS FGFR4 INHIBITORS.
CL2012001911A1 (en) Compounds derived from fumarate; pharmaceutical composition comprising them; and its use in the treatment of an inflammatory or neurodegenerative disease.
CR20120419A (en) FORMULATION OF ANTIBODIES AND THERAPEUTIC REGIMES
NI201500077A (en) NOVELTY BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS
NI201400108A (en) HETEROCYCLYL COMPOUNDS
SG10201810154WA (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CL2013001772A1 (en) Compounds derived from indole and azaindole, as inhibitors of faah; pharmaceutical composition that includes them, useful for the treatment or prevention of pain, autoimmune disorders, inflammatory processes, gastrointestinal diseases, pruritus, substance-related illness, among other diseases.
PE20151501A1 (en) PRMT5 INHIBITORS AND THEIR USES
CL2014002518A1 (en) Nitrogenous heterocyclic derivative compounds, bace-1 or bace-2 inhibitors; pharmaceutical composition that includes them; pharmaceutical combination; its use in the treatment or prevention of Alzheimer's disease or mild cognitive impairment.
UY32487A (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE UNDERSTANDING OXYCODONE AND NALOXONE
CL2013002341A1 (en) Compounds derived from 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4 d] pyrimidin-4-one, pde9a inhibitors; pharmaceutical composition; and its use for the treatment of a disease or condition related to cognitive impairment, Alzheimer's disease, vascular dementia, among others
CO6470898A2 (en) ARIL-PYRIDINS AS INHIBITORS OF SINTASA DE ALDOSTERONA
GT201600269A (en) DERIVATIVES OF INDANO AND INDOLINA AND THE USE OF THE SAME AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE
CY1110097T1 (en) DOUBLE-TESTED DISC FOR PREVENTING HEALTHCARE
CL2014000246A1 (en) Phenyl-3-aza-bicyclo [3.1.0] hex-3-yl-methanone derivative compounds, glycine transporter inhibitors (glyt1); pharmaceutical composition that contains them; pharmaceutical combination; and its use in the treatment of Alzheimer's disease, cognitive disorders in schizophrenia, psychosis, psychiatric disorders, among others
EA201291211A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING HYDROMORPHONE AND NALOXONE
CR20150267A (en) 6 - ((S) -1- {1- [5- (2-HIDROXI-ETOXI) -PIRIDIN-2-IL] 1H-PIRAZOL-3-IL} -ETIL) -3H-1,3-BENZOTIAZOL-2 -ONA AS A RECEPTOR ANTAGONIST AMPA DEPENDENT OF TARP-GAMMA 8
UY35209A (en) TRICYCLIC COMPOUNDS
UY35211A (en) TRICYCLIC COMPOUNDS
BR112015029894A2 (en) solid pharmaceutical dosage form
ECSP10010597A (en) NEW CLASS OF PIPERIDINES ESPIRO FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Legal Events

Date Code Title Description
FB Suspension of granting procedure